PHVS NASDAQ
Pharvaris N.V.
1W: +3.4%
1M: +0.1%
3M: -2.0%
YTD: +20.7%
1Y: +39.0%
3Y: +84.8%
5Y: +109.9%
$31.95
+0.41 (+1.30%)
After Hours: $32.03 (+0.08, +0.27%)
Weekly Expected Move ±6.2%
$28
$29
$31
$33
$35
Credit Risk of going bust: lower than 93% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), Pharvaris N.V. would be worth roughly what it owes.
Total debt $753K against a stock market value of $2.20B.
Distance to default 16.22 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $376K (short-term plus half of long-term), stock volatility 52.9%; Altman Z'' 7.15. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $753K against a stock market value of $2.20B.
Distance to default 16.22 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $376K (short-term plus half of long-term), stock volatility 52.9%; Altman Z'' 7.15. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.2B
52W Range21.02-43.25
Volume230,110
Avg Volume700,113
Beta-2.46
Dividend—
Analyst Ratings
Company Info
CEOBerndt Modig
Employees148
SectorHealthcare
IndustryBiotechnology
IPO Date2021-02-04
Websitepharvaris.com
Grafenauweg 8
Zug, ZH 6300
CH
Zug, ZH 6300
CH
31 71 203 6410
About Pharvaris N.V.
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Latest News
Pharvaris rises after BofA upgrades to Buy
Pharvaris Stock Earnings Estimates Reduced by HC Wainwright
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
Pharvaris (NASDAQ:PHVS) Director Sells $28,952.00 in Stock
Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 14,493 Shares of Stock
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Lu Peng | F-InKind | 117 | $31.10 | 2026-10-12 |
| Lu Peng | F-InKind | 109 | $31.10 | 2026-10-11 |
| Monges Viviane | M-Exempt | 11,969 | $8.05 | 2026-09-23 |
| Monges Viviane | S-Sale | 11,969 | $33.05 | 2026-09-23 |
| Monges Viviane | M-Exempt | 11,969 | $8.05 | 2026-09-23 |